Sika

China still weighs, but medium-term growth levers strengthen

07/10/26 -"We have slightly increased our target price even though marginally reducing our Q3 2026 EBITDA estimates, reflecting ongoing weakness in China and still sluggish residential activity in H2 (20% of ..."

PDF page sample
Pages
47
Language
English
Published on
07/10/26
Download
You may also be interested by these reports :
07/10/26
We have slightly increased our target price even though marginally reducing our Q3 2026 EBITDA estimates, reflecting ongoing weakness in China and ...
14/09/26
Equity markets ended lower on the week ending September 11 as the renewed surge in energy prices revived inflation concerns and pushed bond yields ...
01/09/26
Dormakaba delivered a resilient FY25/26, with 3.0% organic growth, a record 16.1% adjusted EBITDA margin, and stronger H2 momentum. Management guides ...
20/08/26
Our DCF increases as we raise our assumptions following a solid 2Q26 that demonstrated resilience in a still-challenging environment. The group ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO